Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9.

Molecular therapy : the journal of the American Society of Gene Therapy - 6 Jan 2021

Neggers Jasper Edgar, Jacquemyn Maarten, Dierckx Tim, Kleinstiver Benjamin Peter, Thibaut Hendrik Jan, Daelemans Dirk

Abstract excerpt

While drug resistance mutations provide the gold standard proof for drug target engagement, target deconvolution of inhibitors identified from a phenotypic screen remains challenging. Genetic screening for functional in-frame drug resistance mutations by tiling CRISPR-Cas nucleases across protein coding sequences is a method for identifying a drug's target and binding site. However, the applicability of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding Sites
Share to Clustered Regularly Interspaced Short Palindromic Repeats

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Drug Resistance

Share to Endonucleases

Share to Genetic Testing

Share to Mutation

Share to Protein Binding

Source

Open in PubMed Open full text

Identifiers

PMID: 33002419
DOI: 10.1016/j.ymthe.2020.09.025
PMCID: PMC7791016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9.PMID 33002419Read ↗

Optimization of AsCas12a for combinatorial genetic screens in human cellsSemantic proximity Read ↗

CRISPR-Suppressor Scanning for Systematic Discovery of Drug-Resistance Mutations.Semantic proximity Read ↗

Custom CRISPR-Cas9 PAM variants via scalable engineering and machine learning.Semantic proximity Read ↗

AlPaCas: allele-specific CRISPR gene editing through a protospacer-adjacent-motif (PAM) approach.Semantic proximity Read ↗

DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets.Semantic proximity Read ↗

Engineered Un1Cas12f1 for multiplex genome editing with enhanced activity and targeting scope.Semantic proximity Read ↗

Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants.Semantic proximity Read ↗

A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing.Semantic proximity Read ↗

Benchmarking of SpCas9 variants enables deeper base editor screens of <i>BRCA1</i> and <i>BCL2</i>Semantic proximity Read ↗

Engineered FnCas12a with enhanced activity through directional evolution in human cells.Semantic proximity Read ↗

Engineered PAM-flexible FnCas9 variants for robust and specific genome editing and diagnosticsSemantic proximity Read ↗

Rational and computation-assisted engineering of a compact and efficient StaCas9 genome editorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.